ND-2158 is a novel, highly potent and selective interleukin-1 receptor–associated kinase 4 (IRAK4) inhibitor with the potential for the treatment of autoimmune disorders and lymphoid malignancy. It suppressed LPS-induced TNF production, alleviated collagen-induced arthritis, and blocked gout formation in mouse models. IRAK4 inhibition promoted killing of ABC DLBCL lines harboring MYD88 L265P, by down-modulating survival signals, including NF-κB and autocrine IL-6/IL-10 engagement of the JAK–STAT3 pathway.

纯度：≥98%

CAS：1388896-07-8